Edgewise Therapeutics (NASDAQ:EWTX) Stock: Insider Michael Nofi Sells 4,442 Shares

Key Points

• Edgewise Therapeutics CFO Michael Nofi sold 4,442 shares for about $201,800, reportedly to cover tax withholding on vested equity awards; he retained 6,495 shares.
• The stock fell 4.5% to $46.53 in Tuesday trading, with volume above its average.
• Analysts’ consensus rating is “Moderate Buy,” with an average price target of $52.83; the company also reported quarterly EPS of $9.65, ahead of the expected loss of $0.53.

Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) CFO Michael Nofi sold 4,442 shares of the business's stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $45.43, for a total value of $201,800.06. Following the transaction, the chief financial officer directly owned 6,495 shares in the company, valued at $295,067.85. This trade represents a 40.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Edgewise Therapeutics Trading Down 4.5%

Shares of Edgewise Therapeutics stock traded down $2.21 on Tuesday, reaching $46.53. 1,939,581 shares of the company were exchanged, compared to its average volume of 1,293,223. Edgewise Therapeutics, Inc. has a one year low of $18.10 and a one year high of $48.78. The company has a market capitalization of $5.05 billion, a price-to-earnings ratio of 5.68 and a beta of 0.39. The company has a 50-day moving average of $40.97 and a 200 day moving average of $36.64.

Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last released its earnings results on Wednesday, November 4th. The company reported $9.65 earnings per share for the quarter, beating the consensus estimate of ($0.53) by $10.18. Analysts predict that Edgewise Therapeutics, Inc. will post 5.43 earnings per share for the current year.

Wall Street Analysts Forecast Growth

EWTX has been the subject of a number of recent analyst reports. William Blair initiated coverage on shares of Edgewise Therapeutics in a research note on Friday, October 16th. They issued an "outperform" rating for the company. JPMorgan Chase & Co. boosted their price objective on shares of Edgewise Therapeutics from $53.00 to $60.00 and gave the stock an "overweight" rating in a research note on Thursday, August 20th. The Goldman Sachs Group upped their target price on shares of Edgewise Therapeutics from $32.00 to $36.00 and gave the company a "neutral" rating in a report on Tuesday, August 11th. Wedbush dropped their target price on shares of Edgewise Therapeutics from $53.00 to $51.00 and set an "outperform" rating on the stock in a report on Thursday, November 5th. Finally, Evercore reiterated an "outperform" rating and issued a $55.00 target price on shares of Edgewise Therapeutics in a research note on Monday, July 20th. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Edgewise Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $52.83.

Hedge Funds Weigh In On Edgewise Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Parallel Advisors LLC boosted its stake in Edgewise Therapeutics by 64.9% in the first quarter. Parallel Advisors LLC now owns 1,032 shares of the company's stock valued at $33,000 after buying an additional 406 shares in the last quarter. GAMMA Investing LLC grew its position in Edgewise Therapeutics by 26.5% in the third quarter. GAMMA Investing LLC now owns 2,666 shares of the company's stock valued at $108,000 after acquiring an additional 559 shares during the last quarter. AlphaCentric Advisors LLC raised its stake in Edgewise Therapeutics by 4.6% during the third quarter. AlphaCentric Advisors LLC now owns 16,572 shares of the company's stock worth $673,000 after acquiring an additional 732 shares in the last quarter. KBC Group NV acquired a new position in Edgewise Therapeutics during the first quarter worth about $49,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Edgewise Therapeutics by 10.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 20,216 shares of the company's stock worth $792,000 after acquiring an additional 1,843 shares during the last quarter.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for serious muscle disorders. Founded in 2017 and based in Boulder, Colorado, the company researches small-molecule treatments designed to address the underlying biology of muscle and cardiac conditions. Its programs include sevasemten, an investigational therapy for Duchenne and Becker muscular dystrophies, and EDG-7500, an investigational treatment being developed for hypertrophic cardiomyopathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.